Delving into the Latest Updates on Albumin(Evolve Biologics, Inc.) with Synapse

Overview

Basic Info

Drug Type

Blood components

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas-

Active Indication-

Inactive Indication-

Originator Organization

Evolve Biologics, Inc.

Active Organization

Evolve Biologics, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Albumin and albumin-based biomaterials have been explored for various applications, including therapeutic delivery, as therapeutic agents, as components of tissue adhesives, and in tissue engineering applications. Albumin has been approved as a nanoparticle containing paclitaxel (Abraxane®), as an albumin-binding peptide (Victoza®), and as a glutaraldehyde-crosslinked tissue adhesive (BioGlue®). Albumin is also approved as a supportive therapy for various conditions, including hypoalbuminemia, sepsis, and acute respiratory distress syndrome (ARDS). However, no other new albumin-based systems in a hydrogel format have been used in the clinic. A review of publicly available clinical trials indicates that no new albumin drug delivery formats are currently in the clinical development pipeline. Although albumin has shown promise as a carrier of therapeutics for various diseases, including diabetes, cancers, and infectious diseases, its potential for treating blood-borne diseases such as HIV and leukemia has not been translated. This review offers a perspective on the use of albumin-based drug delivery systems for a broader range of disease applications, considering the protein properties and a review of the currently approved albumin-based technologies. This review supports ongoing efforts to advance biomedical research and clinical interventions through albumin-based delivery systems.

01 Apr 2025·Journal of Hepatology

Albumin infusion in Hepatorenal Syndrome-Acute Kidney Injury: new evidence challenges recent consensus.

Review

Author: Caraceni, Paolo ; Kamath, Patrick S ; Singh, Virendra ; Gambino, Carmine ; Piano, Salvatore ; Krag, Aleksander ; Juanola, Adrià ; Trebicka, Jonel ; Marciano, Sebastian ; Maiwall, Rakhi ; Labenz, Christian ; Pose, Elisa ; Sarin, Shiv K ; Ginès, Pere ; Angeli, Paolo ; Galle, Peter R

01 Feb 2025·Indian Pediatrics

Albumin Infusion in Children With Fluid Refractory Severe Dengue: A Comparative Study

Article

Author: Sharma, Mitali ; Bhat, Deepak ; Arora, Kamal ; Kaur, Amandeep ; Pooni, Puneet A ; Gill, Karambir S ; Bhargava, Siddharth ; Dhooria, Gurdeep Singh

OBJECTIVESTo evaluate the effect of 25% albumin in addition to standard treatment (ST) in children with fluid refractory severe dengue on morbidity and mortality compared with ST alone.METHODSThis was a comparative study that enrolled children aged 2 months to 18 years with severe dengue who presented to emergency between 2021-2023. Patients who were in circulatory shock after 40 mL per kg of crystalloid/colloid bolus within 1-2 hours of admission were equally categorized into two groups. ST-plus albumin group enrolled patients prospectively and received an albumin infusion (0.5-1 g/kg) in addition to ST as per WHO guidelines. ST-only group enrolled patients retrospectively who had received only ST. Demographic data, clinical course, laboratory parameters and outcomes were compared.RESULTSBaseline characteristics were comparable between the two groups. Survival was significantly higher in the ST-plus albumin group (97.1%) than in the ST-only group (77.1%); P = 0.043. The need for inotropic support was significantly lower in ST-plus albumin group (60%) than ST-only group (94.3%); P < 0.001. The incidence of bleeding (P = 0.008), AKI (P = 0.065), need for diuretics (P = 0.029) and renal replacement therapy (P = 0.028) were significantly lower in children in the ST-plus albumin group than ST-only group.CONCLUSIONThe addition of 25% albumin to fluid refractory severe dengue early in the disease course led to better survival, less fluid accumulation and bleeding, and lesser incidence of complications.

100 Deals associated with Albumin(Evolve Biologics, Inc.)

Login to view more data

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data